Selonsertib在糖尿病肾脏病患者中的效应
这项2期试验将333例难治性中重度糖尿病肾脏病成人随机分配至selonsertib 2、6、18 mg或安慰剂组,48周eGFR变化主要终点未达统计学差异。事后分析排除20例GCP问题患者后发现,18 mg组4至48周eGFR下降速率较安慰剂组减少71%。
要点
- selonsertib总体安全,48周内未见剂量依赖性不良事件。
- 主要终点48周eGFR变化在selonsertib与安慰剂组间无显著差异。
- 事后分析提示18 mg selonsertib可能减缓eGFR下降,需进一步验证。
核心结论
- 尽管试验未达到主要终点,探索性事后分析提示selonsertib可能减缓糖尿病肾脏病进展。
研究设计与样本
- 2期随机对照试验,纳入333例2型糖尿病合并难治性中重度糖尿病肾脏病成人,按1:1:1:1分配至selonsertib每日口服2、6、18 mg或安慰剂组。
主要发现
- selonsertib 48周内安全,无剂量依赖性不良效应。
- 48周时selonsertib与安慰剂组平均eGFR无显著差异,但selonsertib抑制肌酐分泌的急性效应混淆了eGFR差异。
- 分段线性回归发现两个剂量依赖效应:0至4周更显著的eGFR下降(肌酐分泌效应)和4至48周eGFR下降减缓(治疗效应)。
- 事后分析排除两个中心20例GCP合规问题患者后,18 mg组4至48周年化eGFR下降速率较安慰剂组减少71%(差值3.11±1.53 ml/min per 1.73 m2;95%CI 0.10-6.13;名义P=0.043)。
- selonsertib与安慰剂组尿白蛋白肌酐比值变化无差异。
关键数值与推荐
- 主要终点为48周时eGFR较基线变化。
- 事后分析中18 mg组4至48周年化eGFR下降差值3.11±1.53 ml/min per 1.73 m2(95%CI 0.10-6.13;名义P=0.043)。
临床怎么用
- 目前证据尚不支持临床常规使用selonsertib治疗糖尿病肾脏病,需等待进一步验证。
- 解读eGFR变化时需考虑selonsertib对肌酐分泌的急性抑制效应。
局限性
- 主要终点未达到。
- 治疗效应来自事后分析,且排除了20例GCP合规问题患者,证据等级有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apoptosis signal-regulating kinase 1 (ASK1) activation in glomerular and tubular cells resulting from oxidative stress may drive kidney disease progression. Findings in animal models identified selonsertib, a selective ASK1 inhibitor, as a potential therapeutic agent. METHODS: In a phase 2 trial evaluating selonsertib's safety and efficacy in adults with type 2 diabetes and treatment-refractory moderate-to-advanced diabetic kidney disease, we randomly assigned 333 adults in a 1:1:1:1 allocation to selonsertib (oral daily doses of 2, 6, or 18 mg) or placebo. Primary outcome was change from baseline eGFR at 48 weeks. RESULTS: Selonsertib appeared safe, with no dose-dependent adverse effects over 48 weeks. Although mean eGFR for selonsertib and placebo groups did not differ significantly at 48 weeks, acute effects related to inhibition of creatinine secretion by selonsertib confounded eGFR differences at 48 weeks. Because of this unanticipated effect, we used piecewise linear regression, finding two dose-dependent effects: an acute and more pronounced eGFR decline from 0 to 4 weeks (creatinine secretion effect) and an attenuated eGFR decline between 4 and 48 weeks (therapeutic effect) with higher doses of selonsertib. A post hoc analysis (excluding data for 20 patients from two sites with Good Clinical Practice compliance-related issues) found that between 4 and 48 weeks, rate of eGFR decline was reduced 71% for the 18-mg group relative to placebo (difference 3.11±1.53 ml/min per 1.73 m2 annualized over 1 year; 95% confidence interval, 0.10-6.13; nominal P=0.043). Effects on urine albumin-to-creatinine ratio did not differ between selonsertib and placebo. CONCLUSIONS: Although the trial did not meet its primary endpoint, exploratory post hoc analyses suggest that selonsertib may slow diabetic kidney disease progression.
引用
- Chertow GM, Pergola PE, Chen F, et al. Effects of Selonsertib in Patients with Diabetic Kidney Disease. J Am Soc Nephrol. 2019. PMID: 31506292. doi:10.1681/ASN.2018121231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。